Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 238-238
Open Access | Times Cited: 163

Showing 1-25 of 163 citing articles:

The Role of Adipokines in Health and Disease
Vicente Javier Clemente‐Suárez, Laura Redondo-Flórez, Ana Isabel Beltrán-Velasco, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1290-1290
Open Access | Times Cited: 192
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 2
Polypharmacology: promises and new drugs in 2022
Piotr Ryszkiewicz, Barbara Malinowska, Eberhard Schlicker
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 755-770
Open Access | Times Cited: 28
Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes
Letizia Biso, Stefano Aringhieri, Marco Carli, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 642-642
Open Access | Times Cited: 10
Psychosocial risks in Metabolic dysfunction-associated steatotic liver disease
Hanne Åström, Christine Takami Lageborn, Hannes Hagström
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 1
GPCRs in Intracellular Compartments: New Targets for Drug Discovery
Irene Fasciani, Marco Carli, Francesco Petragnano, et al.
Biomolecules (2022) Vol. 12, Iss. 10, pp. 1343-1343
Open Access | Times Cited: 34
A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis
Kenn Lee, Seri Abraham, Robert Cleaver
General Hospital Psychiatry (2022) Vol. 78, pp. 58-67
Open Access | Times Cited: 27
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Kah Kheng Goh, Cynthia Yi-An Chen, Tzu‐Hua Wu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7092-7092
Open Access | Times Cited: 25
Shared genetics of psychiatric disorders and type 2 diabetes:a large-scale genome-wide cross-trait analysis
Hui Ding, Minyao Xie, Jinyi Wang, et al.
Journal of Psychiatric Research (2023) Vol. 159, pp. 185-195
Closed Access | Times Cited: 16
The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression
Vera Battini, Giovanna Cirnigliaro, Rodolfo Leuzzi, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 15
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis
Fernando Pagán, Paul E. Schulz, Yasar Torres‐Yaghi, et al.
CNS Drugs (2024) Vol. 38, Iss. 5, pp. 333-347
Open Access | Times Cited: 5
The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia
Haylie M. DeMercy, Colleen A. Brenner
Drugs & Aging (2024) Vol. 41, Iss. 10, pp. 847-858
Open Access | Times Cited: 5
Consensus on the key characteristics of metabolism disruptors
Michele A. La Merrill, Martyn T. Smith, Cliona M. McHale, et al.
Nature Reviews Endocrinology (2024)
Open Access | Times Cited: 5
Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review
Filippo Pennazio, Claudio Brasso, Vincenzo Villari, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2674-2674
Open Access | Times Cited: 19
Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
Katherine R. H. Mortimer, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 11
Network pharmacology and molecular docking to explore mechanisms of clozapine-induced cardiac arrest
Ximing Chen, Chuanjun Zhuo, Lei Yang, et al.
Journal of Psychiatry and Neuroscience (2025) Vol. 50, Iss. 1, pp. E1-E10
Open Access
Exploring the therapeutic potential of chlorogenic acid in alleviating olanzapine-induced metabolic syndrome in rats: a key role of hypothalamic satiety proteins
Zeinab Ebrahimian, Bibi Marjan Razavi, Seyed Ali Mousavi Shaegh, et al.
Nutritional Neuroscience (2025), pp. 1-20
Closed Access
Treatment and long-term outcome of mental disorders: the grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries
Konstantinos Ν. Fountoulakis, Grigorios N. Karakatsoulis, Seri Abraham, et al.
Psychiatry Research (2025), pp. 116459-116459
Open Access
The Effect of Lithium Treatment on the Cardiovascular System
Nabel Rajab Basha, Sara Elattar, Ameen Basha, et al.
Cardiology in Review (2025)
Closed Access
Memantine abrogates testicular dysfunction induced by risperidone in rats with a potential role of ERK1/2-Nrf2-caspase-3 signaling pathway
Reham H. Mohyeldin, Ehab E. Sharata, Michael Atef Fawzy, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course
Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 4, pp. 156-156
Open Access
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
Adriana Stelmach, Katarzyna Guzek, Alicja Rożnowska, et al.
Pharmacological Reports (2022) Vol. 75, Iss. 1, pp. 19-31
Open Access | Times Cited: 17
Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics
Marco Carli, Francesco Weiss, Giovanna Grenno, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 4, pp. 935-950
Open Access | Times Cited: 10
Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain
豊田 隆謙, Xiaoyan He, Y. Liu, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 4
Open Access | Times Cited: 10
Impacts of exposure to and subsequent discontinuation of clozapine on tripartite synaptic transmission
Motohiro Okada, Kouji Fukuyama, Eishi Motomura
British Journal of Pharmacology (2024) Vol. 181, Iss. 22, pp. 4571-4592
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top